Open AccessAtypical hemolytic uremic syndrome in high-risk neuroblastoma patient: case report
Author(s) -
А. И. Смирнова,
Ю. В. Диникина,
А. А. Терешина,
Е. П. Евсютина,
М. Б. Белогурова
Publication year - 2021
Publication title -
onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.118
H-Index - 3
eISSN - 2413-4023
pISSN - 1818-8346
DOI - 10.17650/1818-8346-2021-16-1-31-35
Subject(s) - eculizumab , medicine , atypical hemolytic uremic syndrome , neuroblastoma , hemolytic anemia , complement (music) , immunotherapy , complement system , gastroenterology , antibody , immunology , cancer , biology , genetics , cell culture , biochemistry , chemistry , complementation , gene , phenotype
Atypical hemolytic uremic syndrome is a rare disorder uncontrolled complement activation, which is classically manifested by anemia, thrombocytopenia and renal failure. Extrarenal manifestations are observed in 20 % of patients, most of which are associated with damage of the central nervous system. Eculizumab is effective treatment option. The article describes a case report of the severe atypical hemolytic uremic syndrome in a 20 m. o. patient who received immunotherapy with anti-GD2 antibodies (dinutuximab beta) for a high-risk neuroblastoma.